

Basil S Lewis

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3522218/publications.pdf>

Version: 2024-02-01

15
papers

35,193
citations

840776

11
h-index

1125743

13
g-index

15
all docs

15
docs citations

15
times ranked

18628
citing authors

#	ARTICLE	IF	CITATIONS
1	Dabigatran versus Warfarin in Patients with Atrial Fibrillation. <i>New England Journal of Medicine</i> , 2009, 361, 1139-1151.	27.0	9,839
2	Apixaban versus Warfarin in Patients with Atrial Fibrillation. <i>New England Journal of Medicine</i> , 2011, 365, 981-992.	27.0	7,537
3	2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). <i>European Heart Journal</i> , 2021, 42, 373-498.	2.2	5,583
4	2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. <i>European Heart Journal</i> , 2021, 42, 3599-3726.	2.2	5,558
5	Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. <i>Lancet</i> , The, 2014, 383, 955-962.	13.7	3,942
6	Apixaban in Patients with Atrial Fibrillation. <i>New England Journal of Medicine</i> , 2011, 364, 806-817.	27.0	2,207
7	Risk of ischaemic stroke according to pattern of atrial fibrillation: analysis of 6563 aspirin-treated patients in ACTIVE-A and AVERROES. <i>European Heart Journal</i> , 2015, 36, 281-288.	2.2	253
8	Gender differences in the effect of cardiovascular drugs: a position document of the Working Group on Pharmacology and Drug Therapy of the ESC: Figure A1. <i>European Heart Journal</i> , 2015, 36, 2677-2680.	2.2	131
9	Clinical outcomes of patients with diabetes and atrial fibrillation treated with apixaban: results from the ARISTOTLE trial. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2015, 1, 86-94.	3.0	59
10	Oral anticoagulation in patients with non-valvular atrial fibrillation and a CHA2DS2-VASc score of 1: a current opinion of the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy and European Society of Cardiology Council on Stroke. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2019, 5, 171-180.	3.0	46
11	Novel Approaches in Primary Cardiovascular Disease Prevention: The HOPE-3 Trial Rationale, Design, and Participants' Baseline Characteristics. <i>Canadian Journal of Cardiology</i> , 2016, 32, 311-318.	1.7	24
12	Antithrombotic therapy use and clinical outcomes following thrombo-embolic events in patients with atrial fibrillation: insights from ARISTOTLE. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2018, 4, 75-81.	3.0	9
13	Are SGLT2 inhibitors effective against all heart failure with preserved ejection fraction?. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2022, 8, E10-E10.	3.0	5
14	Cardiovascular pharmacotherapy 2015 was a good year. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2016, 2, 209-211.	3.0	0
15	Atrial fibrillation and stroke prevention. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2021, 7, f1-f2.	3.0	0